NeuroVive Pharmaceutical ABの収益YQ/Q

NeuroVive Pharmaceutical ABの収益YQ/Qは何ですか。

NeuroVive Pharmaceutical ABの収益YQ/Qは-63.53%です。

収益YQ/Qの定義は何ですか。

四半期収益成長率、前年比は、前年同期の業績と比較して、売上高の増加率がパーセンテージとして表されています。

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

OTCのセクタHealth Careにおける収益YQ/Qの企業と比べるNeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical ABは何をしますか。

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

NeuroVive Pharmaceutical ABと類似の収益yq/q